Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-223A and AD-223B Combination Therapy in Essential Hypertension
NCT06052748Phase 3Completed
- Sponsor
- Addpharma, Inc.
- Start
- Feb 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of AD-223A in essential hypertension, sponsored by Addpharma, Inc.. Started Feb 2024; status: completed.
02
Drugs
AD-223A
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06052748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06052748.